HJ
Therapeutic Areas
Adverum Biotechnologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ixoberogene soroparvovec (Ixo-vec) | Neovascular (Wet) Age-Related Macular Degeneration (wAMD) | Phase 3 |
Leadership Team at Adverum Biotechnologies
LF
Laurent Fischer, M.D.
President and Chief Executive Officer
RC
Romuald Corbau, Ph.D.
Chief Scientific Officer
AF
Aneta Ferguson
General Counsel
CF
Carla Fiankan
Senior Vice President, Regulatory Affairs
DH
Dena House
Chief People Officer